Company Overview
Snapshot
Founded in August 2017 by Arnon Chait and Roi Feingersch, Foresee Genomics operates with 1–10 employees. The company has raised $2.1M across 4 funding rounds from 3 investors. In February 2024, Foresee Genomics secured funding from GoodPaper Ventures.
Business overview
Foresee Genomics develops a DNA testing system for cancer patients, integrating molecular biology and computational analysis. Their tests provide physicians with genetic data to inform treatment options. The company's procedure utilizes low-cost equipment, enabling point-of-care diagnostics in hospitals and local clinics. Foresee Genomics operates within the Health Tech & Life Sciences sector, specifically focusing on Digital Medical Diagnostics, and serves healthcare providers in markets such as Israel, Europe, and North America.
Log in to access full profile ›Company Intelligence Q&A
- What is Foresee Genomics' primary focus?
- Foresee Genomics is focused on developing a DNA testing system for cancer patients, combining molecular biology and computational analysis to provide genetic data for treatment decisions.
- When was Foresee Genomics founded and by whom?
- Foresee Genomics was founded in August 2017 by Arnon Chait and Roi Feingersch.
- What type of non-equity funding did Foresee Genomics receive?
- In December 2017, Foresee Genomics received a grant from the Israel Innovation Authority.